US FDA approves AbbVie's rare blood cancer drug

The U.S. Food and Drug Administration on Wednesday approved AbbVie's drug to treat blastic plasmacytoid dendritic cell neoplasm, a very rare type of blood cancer.

AbbVie's shares were up more than 1% in afternoon trading.

The approval provides a new treatment option in a setting with limited choices, particularly for patients whose disease has returned or did not respond to earlier treatment.

The drug, pivekimab sunirine‑pvzy, is given through a vein once every three weeks.

The FDA said the drug carries a boxed warning for serious liver problems, including a condition where blood flow in the liver is blocked.

The agency also flagged risks such as reactions during infusion and fluid buildup in the body.

(Reporting by Sahil Pandey in Bengaluru; Editing by Shreya Biswas)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published May 27, 2026 at 3:43 PM.